



ADVERSE DRUG REACTIONS, INCLUDING SJS, TEN

DRUG-INDUCED HYPERSENSITIVITY SYNDROME DUE TO DIAMINODIPHENYLSULFONEDIAPHENY LSULFONE DURING THE TREATMENT OF PEMPHIGUS FOLIACEUS

Akiko Honobe⁽¹⁾ - Manao Kinoshita⁽¹⁾ - Takae Shimizu⁽¹⁾ - Shinya Sano⁽¹⁾ - Hiroshi Mitsui⁽¹⁾ - Shinji Shimada⁽¹⁾ - Tatsuyoshi Kawamura⁽¹⁾

University Of Yamanashi, Dermatology, Chuo, Japan⁽¹⁾

Background: Diaminodiphenylsulfone(DDS) is an antibiotic against Mycobacterium leprae, a causative agent of leprosy. DDS is also applied for a range of medical fields because of its anti-inflammatory and immunomodulatory effect. Drug-induced hypersensitivity syndrome(DIHS),also known as drug rash with eosinophilia and systemic symptoms(DRESS), due to DDS is a rare yet serious adverse drug reaction involving multiple organs. Recently, human leukocyte antigen(HLA)-B*13:01 was identified as a maker of susceptibility to DIHS/DRESS.

Objective: We report a case of 57-year-old Japanese male who developed DIHS/DRESS 33 days after starting DDS for pemphigus foliaceus(PF). The patient presented with a fever, generalized erythematous skin rash, and lymph nodes swelling. Laboratory examination identified leukocytosis, liver dysfunction and atypical lymphocytes, and the diagnosis of DIHS/DRESS was made. The DDS was discontinued immediately and the systemic glucocorticoid therapy(0.6mg/kg/day) was started, however the erythematous lesion and liver dysfunction relapsed and were prolonged. Thus intravenous immunoglobulin(IVIG) therapy and pulse steroid therapy(methylpredonisolone 1000mg/day for three days) were added and he recovered. Since the relationship between DIHS/DRESS and HLA-B*13:01 due to DDS among the patients with leprosy was reported, we examined his HLA and found that he held HLA-B*13:01. Our case suggests that the presence of HLA-B*13:01 may be a risk factor for DDS-induced DIHS/DRESS regardless of an underlying disease. We propose that the HLA-B*13:01 should be examined before starting the DDS to prevent this serious adverse drug reaction.

Key message: We experienced a case of 57-year-old Japanese male with HLA-B*13:01 who developed DIHS/DRESS due to DDS administered for the treatment of PF. Recently, HLA-B*13:01 was identified as a maker of susceptibility to DIHS/DRESS. We propose that the HLA-B*13:01 should be examined before starting the DDS.

